Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Divalproex Sodium Extended-Release tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, as monotherapy and adjunctive therapy and prophylaxis of migraine headaches
The company claims that this is the first time a mental wellness start-up has gone phygital in a Tier 2 city
Subscribe To Our Newsletter & Stay Updated
